GSTM3 deficiency impedes DNA mismatch repair to promote gastric tumorigenesis via CAND1/NRF2-KEAP1 signaling.

[1]  Yoon Young Choi,et al.  Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study , 2021, Annals of Surgical Oncology.

[2]  Donna D. Zhang,et al.  The Intricacies of NRF2 Regulation in Cancer. , 2021, Seminars in cancer biology.

[3]  G. Getz,et al.  DNA polymerase and mismatch repair exert distinct microsatellite instability signatures in normal and malignant human cells. , 2020, Cancer discovery.

[4]  Tao Wang,et al.  DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. , 2020, Cancer cell.

[5]  Microsatellite Instability Causes Repeat Expansion and WRN Dependence. , 2020, Cancer discovery.

[6]  Yi Xie,et al.  NRF2 preserves genomic integrity by facilitating ATR activation and G2 cell cycle arrest , 2020, Nucleic acids research.

[7]  H. Koh,et al.  A Summary of the 2020 Gastric Cancer Summit at Stanford University. , 2020, Gastroenterology.

[8]  Lei Zhang,et al.  C24‐Ceramide Drives Gallbladder Cancer Progression Through Directly Targeting Phosphatidylinositol 5‐Phosphate 4‐Kinase Type‐2 Gamma to Facilitate Mammalian Target of Rapamycin Signaling Activation , 2020 .

[9]  H. Klocker,et al.  The Impact of Cand1 in Prostate Cancer , 2020, Cancers.

[10]  Yi-fan Jia,et al.  DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer , 2019, Cell Death & Differentiation.

[11]  Jie Jin,et al.  The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes , 2018, Haematologica.

[12]  Matthew Slattery,et al.  A distinct class of antioxidant response elements is consistently activated in tumors with NRF2 mutations , 2018, Redox biology.

[13]  Xiaodong Zhu,et al.  Adjuvant therapy in resectable gastric cancer-the CRITICS trial. , 2018, The Lancet. Oncology.

[14]  Donna D. Zhang,et al.  NRF2 and the Hallmarks of Cancer. , 2018, Cancer cell.

[15]  G. Mills,et al.  ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade , 2018, Nature Medicine.

[16]  Xue Xiao,et al.  Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer. , 2018, Gynecologic oncology.

[17]  A. Bass,et al.  Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[19]  Yonglong Zhang,et al.  Hippocalcin‐like 1 suppresses hepatocellular carcinoma progression by promoting p21Waf/Cip1 stabilization by activating the ERK1/2‐MAPK pathway , 2016, Hepatology.

[20]  Debojyoti Pal,et al.  Nrf2 facilitates repair of radiation induced DNA damage through homologous recombination repair pathway in a ROS independent manner in cancer cells. , 2015, Mutation research.

[21]  Gina Manda,et al.  The redox biology network in cancer pathophysiology and therapeutics , 2015, Redox biology.

[22]  D. Cescon,et al.  NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma , 2015, Clinical Cancer Research.

[23]  R. Fishel,et al.  Mismatch repair during homologous and homeologous recombination. , 2015, Cold Spring Harbor perspectives in biology.

[24]  Donna D. Zhang,et al.  Nrf2-Dependent Suppression of Azoxymethane/Dextran Sulfate Sodium–Induced Colon Carcinogenesis by the Cinnamon-Derived Dietary Factor Cinnamaldehyde , 2015, Cancer Prevention Research.

[25]  T. Fujita.  Targeted therapy for gastric cancer. , 2013, The Lancet. Oncology.

[26]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[27]  T. Pandita,et al.  Targeting of Nrf2 induces DNA damage signaling and protects colonic epithelial cells from ionizing radiation , 2012, Proceedings of the National Academy of Sciences.

[28]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[29]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[30]  Jun Liang,et al.  P-0079 Nrf2 Knockdown by Sirna Enhance the Sensitivity to Chemotherapy in Hepatocellular Carcinoma , 2012 .

[31]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[32]  B. Aggarwal,et al.  Oxidative stress, inflammation, and cancer: how are they linked? , 2010, Free radical biology & medicine.

[33]  Kaitlyn N. Lewis,et al.  Nrf2, a guardian of healthspan and gatekeeper of species longevity. , 2010, Integrative and comparative biology.

[34]  Longshan Li,et al.  DNA Mismatch Repair-dependent Activation of c-Abl/p73α/GADD45α-mediated Apoptosis* , 2008, Journal of Biological Chemistry.

[35]  Guo-Min Li,et al.  Mechanisms and functions of DNA mismatch repair , 2008, Cell Research.

[36]  Alex Kiss,et al.  Stage-Specific Effect of Adjuvant Therapy Following Gastric Cancer Resection: a Population-based Analysis of 4,041 Patients , 2008, Annals of Surgical Oncology.

[37]  V. O’Brien,et al.  Signalling cell cycle arrest and cell death through the MMR System. , 2006, Carcinogenesis.

[38]  M. Hannink,et al.  CAND1-Mediated Substrate Adaptor Recycling Is Required for Efficient Repression of Nrf2 by Keap1 , 2006, Molecular and Cellular Biology.

[39]  P. Modrich,et al.  DNA mismatch repair: functions and mechanisms. , 2006, Chemical reviews.

[40]  Hoguen Kim,et al.  Impaired nonhomologous end-joining in mismatch repair-deficient colon carcinomas , 2005, Laboratory Investigation.

[41]  A. Gasbarrini,et al.  Alterations of DNA mismatch repair proteins and microsatellite instability levels in gastric cancer cell lines , 2004, Laboratory Investigation.

[42]  S. Ferrari,et al.  Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. , 2004, Genes & development.

[43]  M. Veigl,et al.  A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage , 2003, Oncogene.

[44]  D. Chang,et al.  Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines. , 2003, Cancer letters.

[45]  M. Kwak,et al.  Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. J. Hickman,et al.  Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Meyers,et al.  Cell cycle regulation of the human DNA mismatch repair genes hMSH2, hMLH1, and hPMS2. , 1997, Cancer research.